Top

Published in:

01-06-2014 | Original Article

Functional thyrotropin receptor expression in the ventricle and the effects on ventricular BNP secretion

Authors: Wen Huang, Jin Xu, Fei Jing, Wen-Bin Chen, Ling Gao, Hai-Tao Yuan, Jia-Jun Zhao

Published in: Endocrine | Issue 2/2014

Abstract

Elevated thyrotropin (TSH) and hypercholesterolemia commonly coexist in patients with subclinical hypothyroidism, which can cause and aggravate heart disease. However, it is unclear whether TSH has a direct effect on cardiac function. To determine the expression of the thyrotropin receptor (TSHR) and the effects of TSH on ventricular function, we analyzed the ventricular tissues and thyroid glands from normal rats and mice and the H9c2 cardiomyocyte cell line. The results revealed that TSHR was expressed at the transcriptional and protein levels by PCR, immunoblotting, immunohistochemistry and immunofluorescence. The mRNA levels of β-MHC and the expression of pCREB and HMGCR in the ventricle were significantly lower in Tshr ^−/− mice than in wild-type (WT) mice (p < 0.05), but serum NT-proBNP levels were similar between WT and Tshr ^−/− mice. After synchronization, H9c2 cells were stimulated with several concentrations of TSH for various time periods. TSH up-regulated β-MHC mRNA expression in H9c2 cells. Cyclic adenosine monophosphate (cAMP) production and downstream signaling, such as pCREB and HMGCR expression and NT-proBNP secretion, increased in dose- and time-dependent manners. The TSH-stimulated effects were suppressed by an adenylyl cyclase inhibitor, a protein kinase A (PKA) inhibitor and HMGCR inhibitors (all p < 0.05). The data indicate functional TSHR is expressed in ventricular myocytes and mediates TSH-induced BNP secretion and HMGCR up-regulation through the cAMP/PKA/pCREB signaling pathway. Our findings suggest a potentially novel pathophysiological role of TSH in heart failure-associated hypothyroidism.

W.I. Khalife, Y.D. Tang, J.A. Kuzman, T.A. Thomas, B.E. Anderson, S. Said, P. Tille, E.H. Schlenker, A.M. Gerdes, Treatment of subclinical hypothyroidism reverses ischemia and prevents myocyte loss and progressive LV dysfunction in hamsters with dilated cardiomyopathy. Am. J. Physiol. 289(6), H2409–H2415 (2005). doi:10.1152/ajpheart.00483.2005

N. Rodondi, D.C. Bauer, A.R. Cappola, J. Cornuz, J. Robbins, L.P. Fried, P.W. Ladenson, E. Vittinghoff, J.S. Gottdiener, A.B. Newman, Subclinical thyroid dysfunction, cardiac function, and the risk of heart failure. The Cardiovascular Health study. J. Am. Coll. Cardiol. 52(14), 1152–1159 (2008). doi:10.1016/j.jacc.2008.07.009 PubMedCentralPubMedCrossRef

N. Rodondi, A.B. Newman, E. Vittinghoff, N. de Rekeneire, S. Satterfield, T.B. Harris, D.C. Bauer, Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death. Arch. Intern. Med. 165(21), 2460–2466 (2005). doi:10.1001/archinte.165.21.2460 PubMedCrossRef

M.D. Danese, P.W. Ladenson, C.L. Meinert, N.R. Powe, Clinical review 115: effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature. J. Clin. Endocrinol. Metab. 85(9), 2993–3001 (2000)PubMed

A.E. Hak, H.A. Pols, T.J. Visser, H.A. Drexhage, A. Hofman, J.C. Witteman, Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann. Intern. Med. 132(4), 270–278 (2000)PubMedCrossRef

J.P. Walsh, A.P. Bremner, M.K. Bulsara, P. O’Leary, P.J. Leedman, P. Feddema, V. Michelangeli, Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. Arch. Intern. Med. 165(21), 2467–2472 (2005). doi:10.1001/archinte.165.21.2467. 165/21/2467 [pii]PubMedCrossRef

C. Xu, X. Yang, W. Liu, H. Yuan, C. Yu, L. Gao, J. Zhao, Thyroid stimulating hormone, independent of thyroid hormone, can elevate the serum total cholesterol level in patients with coronary heart disease: a cross-sectional design. Nutr. Metab. 9(1), 44 (2012). doi:10.1186/1743-7075-9-44 CrossRef

F. Wang, Y. Tan, C. Wang, X. Zhang, Y. Zhao, X. Song, B. Zhang, Q. Guan, J. Xu, J. Zhang, D. Zhang, H. Lin, C. Yu, J. Zhao, Thyroid-stimulating hormone levels within the reference range are associated with serum lipid profiles independent of thyroid hormones. J. Clin. Endocrinol. Metab. 97(8), 2724–2731 (2012). doi:10.1210/jc.2012-1133 PubMedCrossRef

E. Martinez-Quintana, F. Rodriguez-Gonzalez, V. Nieto-Lago, Subclinical hypothyroidism in grown-up congenital heart disease patients. Pediatr. Cardiol. 34(4), 912–917 (2013). doi:10.1007/s00246-012-0571-6 PubMedCrossRef

10.

J.L. Goldstein, M.S. Brown, Regulation of the mevalonate pathway. Nature 343(6257), 425–430 (1990). doi:10.1038/343425a0 PubMedCrossRef

11.

M. Takemoto, J.K. Liao, Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler. Thromb. Vasc. Biol. 21(11), 1712–1719 (2001)PubMedCrossRef

12.

K. Kato, A.D. Cox, M.M. Hisaka, S.M. Graham, J.E. Buss, C.J. Der, Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc. Natl. Acad. Sci. USA 89(14), 6403–6407 (1992)PubMedCentralPubMedCrossRef

13.

S.J. Fuller, J. Gillespie-Brown, P.H. Sugden, Oncogenic src, raf, and ras stimulate a hypertrophic pattern of gene expression and increase cell size in neonatal rat ventricular myocytes. J. Biol. Chem. 273(29), 18146–18152 (1998)PubMedCrossRef

14.

P. Mathiyalagan, L. Chang, X.J. Du, A. El-Osta, Cardiac ventricular chambers are epigenetically distinguishable. Cell Cycle 9(3), 612–617 (2010)PubMedCrossRef

15.

L. D’Amico, I.C. Scott, B. Jungblut, D.Y. Stainier, A mutation in zebrafish hmgcr1b reveals a role for isoprenoids in vertebrate heart-tube formation. Curr. Biol. 17(3), 252–259 (2007). doi:10.1016/j.cub.2006.12.023 PubMedCrossRef

16.

G. Deshpande, A. Godishala, P. Schedl, Ggamma1, a downstream target for the hmgcr-isoprenoid biosynthetic pathway, is required for releasing the Hedgehog ligand and directing germ cell migration. PLoS Genet. 5(1), e1000333 (2009). doi:10.1371/journal.pgen.1000333 PubMedCentralPubMedCrossRef

17.

T. Aoyagi, F. Nakamura, T. Tomaru, T. Toyo-Oka, Beneficial effects of pitavastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, on cardiac function in ischemic and nonischemic heart failure. Intern. Heart J. 49(1), 49–58 (2008)CrossRef

18.

K. Node, M. Fujita, M. Kitakaze, M. Hori, J.K. Liao, Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 108(7), 839–843 (2003). doi:10.1161/01.CIR.0000084539.58092.DE PubMedCentralPubMedCrossRef

19.

D. Grieco, Z.H. Beg, A. Romano, M. Bifulco, S.M. Aloj, Cell cycle progression and 3-hydroxy-3-methylglutaryl coenzyme A reductase are regulated by thyrotropin in FRTL-5 rat thyroid cells. J. Biol. Chem. 265(31), 19343–19350 (1990)PubMed

20.

L. Tian, Y. Song, M. Xing, W. Zhang, G. Ning, X. Li, C. Yu, C. Qin, J. Liu, X. Tian, X. Sun, R. Fu, L. Zhang, X. Zhang, Y. Lu, J. Zou, L. Wang, Q. Guan, L. Gao, J. Zhao, A novel role for thyroid-stimulating hormone: up-regulation of hepatic 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase expression through the cyclic adenosine monophosphate/protein kinase A/cyclic adenosine monophosphate-responsive element binding protein pathway. Hepatology 52(4), 1401–1409 (2010). doi:10.1002/hep.23800 PubMedCrossRef

21.

R. Baliram, L. Sun, J. Cao, J. Li, R. Latif, A.K. Huber, T. Yuen, H.C. Blair, M. Zaidi, T.F. Davies, Hyperthyroid-associated osteoporosis is exacerbated by the loss of TSH signaling. J. Clin. Investig. 122(10), 3737–3741 (2012). doi:10.1172/JCI63948 PubMedCentralPubMedCrossRef

22.

M. Ren, Q. Guan, X. Zhong, B. Gong, Y. Sun, W. Xin, J. Guo, H. Wang, L. Gao, J. Zhao, Phosphatidylinositol 3-kinase/nuclear factor-kappa B signaling pathway is involved in the regulation of IGF-I on Fas-associated death domain-like interleukin-1-converting enzyme-inhibitory protein expression in cultured FRTL thyroid cells. J. Mol. Endocrinol. 38(6), 619–625 (2007). doi:10.1677/JME-07-0020 PubMedCrossRef

23.

W. Zhang, L.M. Tian, Y. Han, H.Y. Ma, L.C. Wang, J. Guo, L. Gao, J.J. Zhao, Presence of thyrotropin receptor in hepatocytes: not a case of illegitimate transcription. J. Cell Mol. Med. 13(11–12), 4636–4642 (2009). doi:10.1111/j.1582-4934.2008.00670.x PubMedCrossRef

24.

R. Paschke, V. Geenen, Messenger RNA expression for a TSH receptor variant in the thymus of a two-year-old child. J. Mol. Med. 73(11), 577–580 (1995)PubMedCrossRef

25.

T. Endo, K. Ohta, K. Haraguchi, T. Onaya, Cloning and functional expression of a thyrotropin receptor cDNA from rat fat cells. J. Biol. Chem. 270(18), 10833–10837 (1995)PubMedCrossRef

26.

M. Mengistu, Y.G. Lukes, E.V. Nagy, H.B. Burch, F.E. Carr, S. Lahiri, K.D. Burman, TSH receptor gene expression in retroocular fibroblasts. J. Endocrinol. Invest. 17(6), 437–441 (1994)PubMed

27.

V. Drvota, A. Janson, C. Norman, C. Sylven, J. Haggblad, M. Bronnegard, C. Marcus, Evidence for the presence of functional thyrotropin receptor in cardiac muscle. Biochem. Biophys. Res. Commun. 211(2), 426–431 (1995). doi:10.1006/bbrc.1995.1831 PubMedCrossRef

28.

D.F. Sellitti, R. Hill, S.Q. Doi, T. Akamizu, J. Czaja, S. Tao, H. Koshiyama, Differential expression of thyrotropin receptor mRNA in the porcine heart. Thyroid 7(4), 641–646 (1997)PubMedCrossRef

29.

B.E. Busuttil, A.G. Frauman, Extrathyroidal manifestations of Graves’ disease: the thyrotropin receptor is expressed in extraocular, but not cardiac, muscle tissues. J. Clin. Endocrinol. Metab. 86(5), 2315–2319 (2001)PubMed

30.

B. Biondi, Mechanisms in endocrinology: heart failure and thyroid dysfunction. Eur. J. Endocrinol./Eur. Fed. Endocr. Soc. 167(5), 609–618 (2012). doi:10.1530/EJE-12-0627 CrossRef

31.

G. Iervasi, G. Nicolini, Thyroid hormone and cardiovascular system: from basic concepts to clinical application. Intern. Emerg. Med. 8(Suppl 1), S71–S74 (2013). doi:10.1007/s11739-013-0911-4 PubMedCrossRef

32.

T.L. Broderick, M. Jankowski, D. Wang, B.A. Danalache, C.R. Parrott, J. Gutkowska, Downregulation in GATA4 and Downstream Structural and Contractile Genes in the db/db Mouse Heart. ISRN Endocrinol. 2012, 736860 (2012). doi:10.5402/2012/736860 PubMedCentralPubMedCrossRef

33.

W.J. Remme, K. Swedberg, Task force for the, D., treatment of chronic heart failure, E.S.o.C.: guidelines for the diagnosis and treatment of chronic heart failure. Eur. Heart J. 22(17), 1527–1560 (2001). doi:10.1053/euhj.2001.2783 PubMedCrossRef

34.

P.F. Downie, S. Talwar, I.B. Squire, J.E. Davies, D.B. Barnett, L.L. Ng, Assessment of the stability of N-terminal pro-brain natriuretic peptide in vitro: implications for assessment of left ventricular dysfunction. Clin. Sci. 97(3), 255–258 (1999)PubMedCrossRef

35.

S.J. Watkins, G.M. Borthwick, H.M. Arthur, The H9C2 cell line and primary neonatal cardiomyocyte cells show similar hypertrophic responses in vitro. In vitro cellular & developmental biology. Animal 47(2), 125–131 (2011). doi:10.1007/s11626-010-9368-1

36.

T. Kimura, A. Van Keymeulen, J. Golstein, A. Fusco, J.E. Dumont, P.P. Roger, Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro models. Endocr. Rev. 22(5), 631–656 (2001)PubMedCrossRef

37.

A. Bell, A. Gagnon, P. Dods, D. Papineau, M. Tiberi, A. Sorisky, TSH signaling and cell survival in 3T3-L1 preadipocytes. Am. J. Physiol. Cell Physiol. 283(4), C1056–C1064 (2002). doi:10.1152/ajpcell.00058.2002 PubMedCrossRef

Title: Functional thyrotropin receptor expression in the ventricle and the effects on ventricular BNP secretion
Authors: Wen Huang
Jin Xu
Fei Jing
Wen-Bin Chen
Ling Gao
Hai-Tao Yuan
Jia-Jun Zhao
Publication date: 01-06-2014
Publisher: Springer US
Published in: Endocrine / Issue 2/2014
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-013-0052-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2014

Additive effect of heavy metals on metabolic syndrome in the Korean population: the Korea National Health and Nutrition Examination Survey (KNHANES) 2009–2010

Is there a need for yet another staging system for differentiated thyroid cancer?

The calcium–phosphate balance, modulation of thyroid autoimmune processes and other adverse effects connected with thyroid arterial embolization

Hyperhomocysteinemia is an independent predictor of sub-clinical carotid vascular damage in subjects with grade-1 hypertension

Association between leisure time physical activity and metabolic syndrome: a meta-analysis of prospective cohort studies

Somatostatin and diabetic retinopathy: current concepts and new therapeutic perspectives

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials